The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer. The ESG in Life Sciences Summit West is coming ...

including Johnson & Johnson and AstraZeneca. Cytokinetics is said to be holding out for between $130 to $145 a share, according to Betaville, citing sources familiar with the matter, but ...